New pre-print from the group in collaboration with AD3, UKHSA. We report new generation modified azole antifungals against multidrug-resistant Candida auris | ChemRxiv - go.shr.lc/4edhRxc

We had a great World Pharmacists Day talk today hosted School of Cancer & Pharmaceutical Sciences King's College London Pharmacy 🌈 by @MagsWatson1 from University of Strathclyde . Mags talked about ‘The medicine-related needs of older people with sensory impairment’. One of the best talks of the IPS Seminar Series.

Congratulations to the newest PhD graduate from ⁦Drug Discovery Research Lab KCL⁩ Dr Peiqin Jin who led a project on NFkB targeting PROTACss as cancer therapy, co-supervised by ⁦Chris Pepper⁩ and ⁦David Thurston⁩. Thanks to ⁦Simon Mitchell⁩ and ⁦Robert Falconer⁩ for examining.

Poster presentation at large academic conferences. 😂

We are hosting Professor David Nutt from ⁦Imperial College London⁩ as part of ⁦School of Cancer & Pharmaceutical Sciences⁩ IPS seminar series today. David is giving an intriguing talk on the use of psychedelics as future treatments of brain disorders. Fascinating insights on psychedelics!!!

Hear from our group lead Prof Miraz Rahman about the threat posed by AMR, current research and what needs to happen across govt and industry to tackle this urgently.

It’s that time of the year to enjoy a meal together and reflect on the achievements and activities of 2024. ⁦Drug Discovery Research Lab KCL⁩ members enjoyed their Christmas lunch at Kachori restaurant on Monday. We had a wonderful time together!!

We enjoyed ⁦Drug Discovery Research Lab KCL⁩ quarterly Potluck lunch today. Food from 12 different cuisines. Mohammad won with his Afghan cuisine while Paolo was the runner up with his Italian food. Everyone cooked some supper yummy food.

New paper from the group in collaboration with UK Health Security Agency AD3, UKHSA . C7-Substituted Quinolines as Potent Inhibitors of AdeG Efflux Pumps in Acinetobacter baumannii | ACS Infectious Diseases pubs.acs.org/doi/10.1021/ac…

Our group PI Prof Miraz Rahman recently sat down with Nature to discuss the role artificial intelligence (AI) can play in transforming drug discovery and development. The article featuring his opinion has been published today, and you can read it here nature.com/articles/d4158….

New collaborative paper from Drug Discovery Research Lab KCL School of Cancer & Pharmaceutical Sciences with Professor Ramon Vilar Imperial College London. Discovery of Phototoxic Metal Complexes with Antibacterial Properties via a Combinatorial Approach | Inorganic Chemistry pubs.acs.org/doi/full/10.10…

Prof Prof Miraz Rahman has been awarded a grant by LifeArc to develop effective antibiotics for people with cystic fibrosis The drugs will target a pathogen that causes chronic lung infections in people with the condition Read more ⤵️ kcl.ac.uk/news/grant-sup…

This grant from LifeArc gives us the opportunity to develop our new efflux resistant antibiotics for treating infections associated with Cystic Fibrosis. It’s a joint project between King's College London and AD3, UKHSA.

Our new RSC Medicinal Chemistry paper led by Paolo Andriollo describes a new class of antibody drug conjugate payload that, in a pancreatic cancer model, drives complete tumour regression for 60 days after a single 2 mg/kg dose - outperforming 10 mg/kg Enhertu. pubs.rsc.org/en/content/art…

Prof Miraz Rahman, Professor of Medicinal Chemistry, has been elected as an Expatriate Fellow of the Bangladesh Academy of Sciences (BAS) This was for his significant contributions to scientific research. He is the first British Bangladeshi scientist to receive this fellowship 👏

As a British Bangladeshi academic, it is a great honour and privilege to be recognised by the Bangladesh Academy of Sciences (BAS) as an Expatriate Fellow. I look forward to working with Bangladesh Academy of Sciences (BAS) to help advance scientific research in Bangladesh.

Candida auris is a dangerous fungal pathogen that has become a global health concern Scientists from King's have developed a new class of antifungal compounds that could offer a powerful weapon against it kcl.ac.uk/news/antifunga…

Excited to share a new class of azole antifungals from our group that are effective against multidrug-resistant Candida auris. These efflux-resistant molecules exhibit broad-spectrum activity and are advancing towards preclinical development. Supported by UK Health Security Agency and NIAID News